Tasmanian Devils Developing Resistance to Transmissible Cancer

The marsupials’ genomes show evidence of a rapid evolutionary response to selection imposed by devil facial tumor disease.

Written byAbby Olena, PhD
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, KERESHDuring the last 20 years, a contagious cancer has decimated Tasmanian devil (Sarcophilus harrisii) populations. Cancer cells, which are spread by biting, grow deadly tumors on the faces and mouths of the aggressive marsupials. Because devil facial tumor disease (DFTD) has been observed in almost all known populations and is nearly 100 percent fatal, epidemiological models have suggested that the most long-infected populations are facing extinction.

“But they’re currently surviving,” said Andrew Storfer of Washington State University. Now, he and his colleagues have the start of an explanation as to why. In a study published today (August 30) in Nature Communications, Storfer and an international team of researchers reported genomic evidence to suggest that Tasmanian devils are evolving resistance to DFTD.

“It’s such an important finding,” said Beata Ujvari of Deakin University in Geelong, Australia, who did not participate in the work. “We suspected that the devils would evolve resistance to the disease,” she added. “It was really exciting to see that this hunch or hypothesis was actually correct.”

Storfer and colleagues scanned the genomes of 294 Tasmanian devils from three locations across the Australian island, examining tissue samples collected both ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies